PubMed Health⌕ Search

Biomedical subjects

C Kirchoff

Publications and source records attributed to C Kirchoff.

5 recordsLinked to original sources
PubMed1977

Pretransplant monitoring of donor-recipient compatibility.

In these studies, pretransplant testing of donor-recipient compatibility was performed in 10 related donor and 26 cadaveric renal transplants using a variety of cell-mediated immunity tests. Mixed lymphocyte culture results did not correlate with acute rejection (AR), acute irreversible rejection, or chronic rejection (CR). Lymphocyte-mediated cytolysis also did not correlate with AR, acute irreversible rejection, or CR. Cell-mediated lympholysis correlated with AR but not with acute irreversible rejection or CR. Antibody-dependent cell-mediated cytolysis (ADCMC) was positive pretransplant in 13 (36%) of the recipients. Of the positive patients, 4 had early severe AR and 9 developed typical CR. Of these 13 patients, 9 or 69% lost graft function to rejection whereas only 3 of 20 (15%) of ADCMC-negative patients lost graft function because of rejection (P less than 0.05). In summary, cell-mediated lympholysis testing demonstrated a capability to predict AR episodes. The most useful pretransplant monitoring assay in this patient series was the ADCMC assay. A positive ADCMC against donor cells pretransplant indicates a relatively poor prognosis for long-term graft survival.

Antibody-Dependent Cell Cytotoxicity↗
PubMed1972

In vitro susceptibility testing with tobramycin.

Tobramycin (nebramycin factor 6) is an aminoglycoside antibiotic active in vitro against many gram-negative species and Staphylococcus aureus. The susceptibility of 191 recently isolated pathogenic bacteria to tobramycin was measured by both a routine broth dilution procedure and the FDA standardized disc technique using a 10-mug disc. Twenty-five isolates each of Escherichia, Enterobacter, Klebsiella, indole-negative Proteus, Pseudomonas, Serratia, and S. aureus, and 16 isolates of group D enterococci were tested. The greatest activity was seen with S. aureus and Pseudomonas species; nearly all isolates of both were inhibited by 0.20 mug or less per ml. Tobramycin was slightly less active against Klebsiella and Enterobacter and moderately active against Escherichia and Proteus, with most isolates of these genera being inhibited by 1.56 mug/ml. Neither Serratia nor the enterococci were particularly susceptible. Correlations between zones of inhibition around the 10-mug disc and minimal inhibitory concentrations were determined, and a zone diameter of 16 mm was recommended as the critical point for prediction of susceptibility.

Aminoglycosides↗